GLP-1 agonist

New Slimming Meds of 2026

In 2026, new weight-loss drugs will target more receptors, hit new metabolic pathways, and may come in pill form.

Lemme GLP-1’s lemon extract, Eriomin, may boost GLP-1 levels slightly, but research shows this won’t cause weight loss or appetite suppression.

It’s more important than you might think to take Rybelsus with minimal water on an empty stomach and waiting at least 30 minutes before eating.

Ozempic and Mounjaro are highly effective at treating obesity, however there are many other approved and off-label options that also work.

New obesity drugs target more than just GLP-1 and do much more than suppress appetite for a more nuanced approach to weight loss.

White or Asian younger women who use metformin and have lower sugar and lipid levels tend to experience more weight loss with Mounjaro.

Orforglipron, Semaglutide, and Danuglipron are oral GLP-1 agonists that are all similar enough that cost may end up being the winning factor.

Eli Lilly’s retatrutide has shown stronger weight loss effects than others we’ve seen so far. However, it may have additional heart risks.

The current evidence suggests that GLP-1 agonists do not cause suicidal thoughts. In fact, they may actually be beneficial for depression.

Pfizer’s danuglipron may give Ozempic a run for its money, however has not proven itself to be as effective as Wegovy for weight loss.

Research shows that Ozempic and Wegovy aid in weight loss for about a year. However, despite continued usage, weight regain is common.

Using low-fat diets or consuming too many sweet foods can potentially reduce the effectiveness of Ozempic or Wegovy.